The QualityStocks Daily Wednesday, January 22nd, 2020

Today's Top 3 Investment Newsletters

SmallCapRelations (GWPD) +66.67%

MissionIR (GNPX) +64.35%

QualityStocks (BIVI) +50.00%

The QualityStocks Daily Stock List

Torque Esports Corp. (MLLLF)

Small Cap Power, OTC Markets, Penny Stock Hub, OTC.Watch, TradingView, Investing News, Macroaxis, Financial Buzz, Morningstar, Streaming Media, InvestorsHub, Seeking Alpha, Stockwatch, PR Newswire, Barchart, and Stockhouse reported previously on Torque Esports Corp. (MLLLF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Torque Esports Corp.is a mobile gaming publisher. The Company provides solutions in the areas of e-sports racing and professional motorsports globally. Torque Esports is working to revolutionize esports racing and the racing gaming genre through its industry-leading gaming studio Eden Games. Torque was previously known as Millennial Esports Corp. It changed its name to Torque Esports Corp. in October of 2019. Torque has operations in North America and in Europe. The Company is based in Toronto, Ontario.

Eden Games centers on mobile racing games and its inventive motorsport IP. This includes World's Fastest Gamer (created and managed by wholly-owned subsidiary IDEAS+CARS, Silverstone UK). With simulator company AiS recently added – Torque Esports offers gamers everything from Free to Play mobile games to the highest end simulators. Allinsports (AiS) is a go-to hardware provider for racing simulators for F1 and pro racing drivers. Since its inception in 2009, AiS has been a technical partner of the Ferrari Driver Academy. It is a technical partner to Ferrari in simulator development.

Stream Hatchett is also a wholly-owned subsidiary of Torque. Through this subsidiary, Torque provides strong esports data and management information to brands, sponsors, and industry leaders. Stream Hatchet is a data analytics/intelligence company centered on live streaming analytics, E-Sports industry research, API services and consulting services. Stream Hatchet enables organizations to identify influences and trends through collecting data and turning it into metrics that help target ads at the right audience. Moreover, Torque’s tournament organizing arm, UMG, has recently added a digital tournament platform to its portfolio of assets in its ever-increasing ecosystem.

Fundamentally, Torque Esports’ core business segments include gaming content production, data, esports events and content production, and also hardware. Its growth strategy is via acquisition of complementary gaming and esports assets to drive the existing ecosystem.

Last week, Torque Esports, Frankly, Inc. (TLK.V) (FRNKF), and WinView, Inc. announced that the parties have entered into an amendment to the binding letter agreement earlier entered into by the parties regarding a business combination involving all three companies. The parties have agreed to extend the deadline to enter into a definitive agreement for the Transaction from January 10, 2020 to January 24, 2020 .

Torque Esports Corp. (MLLLF), closed Wednesday's trading session at $1.7499, up 8.6894%, on 3,969,900 volume with 48 trades. The average volume for the last 3 months is 62,890 and the stock's 52-week low/high is $0.414999991/$7.50.

chart

Acreage Holdings, Inc. (ACRGF)

NetworkNewsWire, New Cannabis Ventures, The Cannabis Investor, Investor's Business Daily, TipRanks, Street Insider, TMXmoney, Dividend Investor, TradingView, Investing News, Proactive Investors, Investing.com, MarketBeat, Market Screener, MarijuanaStocks.com, OTC Markets, Stockwatch, and InvestorsHub reported beforehand on Acreage Holdings, Inc. (ACRGF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Acreage Holdings, Inc. is one of the largest vertically integrated, multi-state operators of cannabis licenses and assets in the U.S. The Company owns licenses to operate or has management or consulting services or other agreements in place with license holders to assist in operations in 20 States (including pending acquisitions). OTCQX-listed, Acreage Holdings is based in New York, New York.

In 2018, Acreage Holdings’ national retail store brand, The Botanist, debuted. The Botanist provides an immersive, educational hub for people who desire to live a balanced and socially responsible lifestyle. Acreage’s products are uniquely formulated to help consumers experience a more holistic path to health and wellness.

From seed to sale, Acreage Holdings emphasis is on creating industry standards that deliver the highest quality products and experiences. The Company’s business model includes Cultivation, Process Manufacturing, Dispensing, as well as Consumer Brands. Along with the Botanist, Acreage Holdings has its Prime brand. This is a first-rate brand of medical cannabis, from seed to sale. Prime centers on advancing health and wellness and delivering premier quality, pesticide-free products designed for precise dosing and medicating.

Acreage also has its Live Resin Project brand. Live Resin Project offers an innovative line of vapes and concentrates crafted using unique extraction methods, which use the whole cannabis plant. In addition, Acreage has its Natural Wonder brand. This is a lifestyle brand of fast-acting, discreet and effective breath sprays formulated with natural ingredients and combined with first-class cannabinoids.

Last week, Acreage Holdings announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), expired regarding the proposed acquisition of Deep Roots Medical LLC (d/b/a Deep Roots Harvest). The expiration of the waiting period under the HSR Act satisfies one condition required to close the transaction, which remains subject to certain other customary closing conditions.

Acreage Holdings announced, on April 18, 2019, that its subsidiary, High Street Capital Partners, LLC (HSCP), entered into an agreement to acquire 100 percent of Deep Roots Harvest, a vertically integrated cannabis operator in Nevada, for a total transaction value of $120 million to be paid in equity of HSCP and cash.

Acreage Holdings, Inc. (ACRGF), closed Wednesday's trading session at $6.49, up 0.620155%, on 44,387 volume with 606 trades. The average volume for the last 3 months is 325,869 and the stock's 52-week low/high is $3.83999991/$30.00.

chart

H/Cell Energy Corporation (HCCC)

Stock Day Media, Uptick Newswire, MarketBeat, OilandGas360, Financial Buzz, OTC Markets, Street Insider, 4-Traders, Stockwatch, FairlyValued, Market Screener, Simply Wall St, Stockhouse, Wallet Investor, Morningstar, and last10k reported earlier on H/Cell Energy Corporation (HCCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

H/Cell Energy Corporation designs and implements clean energy solutions featuring hydrogen and fuel cell technology. The OTCQB-listed Company is an integrator that concentrates on the design and implementation of clean energy solutions. This includes solar, battery, fuel cell and hydrogen generation systems. Via its subsidiaries, the Company also provides environmental systems and security systems integration. H/Cell Energy is headquartered in Dallas, Texas.

The Company serves the residential, commercial and government sectors. It has developed and implemented a hydrogen energy system used to totally power a residence or commercial property with clean energy. This is so it can run independent of the utility grid and also provide energy to the utility grid for monetary credits. This innovative system utilizes renewable energy as its source for hydrogen production.

The HC-1 system is designed to provide clean energy for a better environment. The system eliminates the electric bill and dependence on fossil fuels. In addition, it allows one to benefit with tax and energy credits while helping make the environment safe for future generations. The HC-1 system is completely scalable. Upon installation, the HC-1 system operates as a self-sustaining energy system providing electricity and/or hydrogen fuel for transportation.

The design of each HC-1 system is to accommodate the electrical loads for an end user. This system can be configured to meet any kilowatt hour (kWh) demands. The installation includes solar panels, a hydrogen generator, a fuel cell and a tank that would be located exterior to the property with the battery system located interior to the property.

Last week, H/Cell Energy announced that it was awarded $800k in new contracts for renewable energy, environmental systems, as well as general contracting. These contracts include work to be completed at different locations in the United States and Australia including Queensland Rail, Ergon Energy, Healy State School, Mossman State High School, University of Pennsylvania Health System and Coca Cola.

H/Cell Energy Corporation (HCCC), closed Wednesday's trading session at $0.75, even for the day, on 2,544,583 volume with 2 trades. The average volume for the last 3 months is 2,196 and the stock's 52-week low/high is $0.25/$1.60000002.

chart

InterCure Ltd. (IRCLF)

Profit Confidential, OTC Markets, Stock Target Advisor, PredictWallStreet, TeleTrader, Stockwatch, Wallet Investor, Tiingo, Barchart, Cannabis Stock Trades, TipRanks, GuruFocus, TradingView, Morningstar, Dividend Investor, YCharts, Stockhouse and Macroaxis reported earlier on InterCure Ltd. (IRCLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

InterCure Ltd. invests in the biomedical, life sciences, as well as biotechnology sectors in Israel and around the world. The Company’s wholly-owned subsidiary is Canndoc. This subsidiary has been pioneering Pharma-Grade medical cannabis for greater than 11 years.

Established in 1994, InterCure has its corporate headquarters in Israel. The Company’s shares trade on the OTC Markets. The Company was previously known as Ben Gavish Ltd. It changed its name to InterCure Ltd. in June of 1997.

Over the years, the Canndoc subsidiary has provided greater than 500,000 doses to 15,000 patients. Canndoc has demonstrated considerable expertise across the entire value chain. This is from research, cultivation, and processing, to product development and advanced GMP (Good Manufacturing Practices) clinical trials pipeline initiation.

Canndoc delivers GMP Pharma-Grade cannabis solutions to attain better patient health and treatment outcomes. Canndoc's medicinal cannabis clinical pipeline includes late stage studies validating its GMP Pharma-Grade cannabis products for epilepsy, fibromyalgia, neuropathic pain, side effects of chemotherapy in cancer patients, Parkinson's disease, rheumatic arthritis, radicular pain, posttraumatic stress disorder (PTSD), and lumbar radiculopathy.

This past November, InterCure announced that its Canndoc subsidiary initiated a Phase 3 clinical trial with the Shamir Medical Center (Assaf HaRofeh) for the treatment of children with autism spectrum disorder. This program will be led by Dr. Orit Stoller, a pediatric neurologist at the Autism Center at Shamir (Assaf HaRofeh), and Prof. Mati Berkovitch, Head of the Clinical Pharmacology Unit at the Shamir Medical Center (Assaf HaRofeh), validating the safety and efficacy of Canndoc's GMP Pharma Grade cannabis product T1/C20 for children with autism spectrum disorder. Assaf HaRofeh Medical Center is one of the largest leading government hospitals in Israel.

Alon Granot, Chief Executive Officer of Canndoc, said, "Our late stage clinical trial pipeline places Canndoc at the forefront of global clinical GMP-standard medical cannabis research. We are delighted to initiate Phase 3 trial with the most experienced and devoted physicians team bringing hope to these special kids and their families."

InterCure Ltd. (IRCLF), closed Wednesday's trading session at $1.21, up 21.00%, on 5,501 volume with 4 trades. The average volume for the last 3 months is 6,804 and the stock's 52-week low/high is $0.949999988/$4.3499999.

chart

NanoXplore, Inc. (NNXPF)

Penny Stock Hub, Stock Pulse, OTC Markets, InvestorX, Stock Target Advisor, Junior Mining Network, Dividend Investor, 4-Traders, GuruFocus, GlobeNewswire, Seeking Alpha, Canadian Insider, TradingView, Barchart, Global Banking and Finance, OTC.Watch, Investors Hangout, Wallet Investor, PR Newswire, Stockwatch, Dividend.com, Stockhouse and Morningstar reported previously on NanoXplore, Inc. (NNXPF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NanoXplore, Inc. is a graphene company listed on the OTC Markets Group’s OTCQX. It manufactures and supplies graphene powder for use in industrial markets. The Company operates in the United States, Canada, France, Switzerland, as well as internationally. In essence, NanoXplore provides standard and custom graphene-enhanced plastic and composite products to assorted customers in transportation, packaging, electronics, as well as other industrial sectors.

Established in 2011, the Company has its corporate office in Montreal, Quebec. It also has manufacturing facilities throughout North America and Europe. The Company is the largest Canadian producer of graphene today (25 tonnes/year).

NanoXplore offers graphene-based solutions, including GrapheneBlack powder, graphene-plastic masterbatch pellets, and graphene-enhanced polymers. In addition, the Company provides standard and custom enhanced thermoplastic products to various customers. NanoXplore own its unique, proprietary, and patent-protected graphene manufacturing technology, which provides a substantial cost-effective solution to its customers in high-volume applications. The Company is becoming an international graphene player with a completely -financed 10,000 tonnes/year production facility with scheduled Phase One operation to be completed in Q1 2020.

NanoXplore’s family of acquisitions within composite materials provide direct access to worldwide Original Equipment Manufacturers (OEMs). This shortens the product procurement timeline on new graphene-enhanced applications. The Company has a $10M project with Sustainable Development Technology Canada (SDTC), a Government of Canada foundation. This project is for metal replacement with graphene-enhanced plastics within the electric transportation marketplace.

Last week, NanoXplore provided an operational update on its new commercial graphene facility in Montreal (Ville St-Laurent), Quebec. Its new graphene production facility is presently housed within an existing 70,000 square foot building. All major equipment has been delivered and secured in their physical location within the facility. Mechanical and electrical connections of the equipment are continuing and are expected to be completed by early February 2020. This facility in Montreal became the Company’s new corporate headquarters on January 20th, 2020.

Mr. Rocco Marinaccio, Chief Operating Officer of NanoXplore, said, “It has been an extremely busy six-month period for the Operations team, but I’m delighted to report that all major equipment for our 4,000 metric tons/year commercial graphene initiative has been delivered and we remain on-time and below budget for the project. Focus will now shift to the integration of the equipment with scheduled commissioning to start during February of this year.”

NanoXplore, Inc. (NNXPF), closed Wednesday's trading session at $1.11068, off by 1.1235%, on 56,650 volume with 9 trades. The average volume for the last 3 months is 2,796 and the stock's 52-week low/high is $0.850000023/$1.22000002.

chart

Puration, Inc. (PURA)

Emerging Growth, Beat Penny Stocks, Stock of the Week, Small Cap Exclusive, CannabisMarketCap, OTC Markets, TMXmoney, TradingView, Nasdaq, GlobeNewswire, InvestorsHub, Central Charts, OTC PR Wire, GuruFocus, Insider Financial, Proactive Investors, Market Screener, PR Newswire, Stockhouse, and Wallet Investor reported beforehand on Puration, Inc. (PURA), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Puration, Inc. is the producer of EVERx CBD Infused Sports Drink, the leading CBD (cannabidiol) beverage in the sports nutrition marketplace. The Company launched the EVERx CBD Infused Sports Waters in the Spring of 2017. Its sales grew 600 percent in the first year after the launch of EVERx. EVERx has more than twice the CBD of most CBD infused waters on the market.

Puration attained $1 million in revenue in 2018 and then reported another $1 million in revenue in the first six months of 2019. Puration lists on the OTC Markets. The Company is based in Farmers Branch, Texas.

Puration is reorganizing to concentrate its efforts on the cannabis beverage industry. It is implementing an acquisition campaign targeting other cannabis beverage operations as part of an overall strategy to hasten an expansion of its portfolio of cannabis beverage brands.

Puration announced Wednesday, January 15, 2020 as the official launch of its 2020 EVERx CBD Sports Water Marketing Campaign. The Company announced the anchor event around which its 2020 EVERx CBD Sports Water Marketing Campaign will center. Since its launch three years ago, EVERx has become the top CBD infused beverage in the sports nutrition marketplace. EVERx now has distribution in Europe, Latin America, and Africa in addition to within the U.S.

Puration is exploring the acquisition of KALY CBD confection assets. This week, Puration announced the two companies entered into discussions concerning Puration’s possible acquisition of these assets. KALY recently announced plans to consolidate its business structure and concentrate on its Cannabis Biopharmaceutical Technology, spinning of its non-pharmaceutical business assets.

KALY has a U.S. Patented Cannabis Extraction Process. It is developing treatments for different medical conditions. This technology has been valued at $50 million in conjunction with a recent acquisition offer that KALY management passed on. Currently, Puration owns the sole license of KALY's Patented Cannabis Extraction Process for extracts to be infused into beverages.

Puration, Inc. (PURA), closed Wednesday's trading session at $0.038, up 3.5422%, on 200,886 volume with 155 trades. The average volume for the last 3 months is 2,247,903 and the stock's 52-week low/high is $0.03596/$0.150000005.

chart

ReNeuron Group plc (RNUGF)

Zacks, Whale Wisdom, Wallmine, Future Medicine, StockInvest.us, AnalystRatings, InvestorsHub, TipRanks, Barchart, MacroTrends, GuruFocus, dividata, YCharts, Investors Hangout, Seeking Alpha, Macroaxis, Trading View, Wallet Investor, and Morningstar reported earlier on ReNeuron Group plc (RNUGF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ReNeuron Group plc is a foremost, clinical-stage stem cell business. The Company’s chief goal is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its innovative stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the requirement for additional drug treatments. ReNeuron Group lists on the OTC Markets. The Company’s headquarters and laboratories are in Pencoed, the United Kingdom (UK).

ReNeuron’s therapeutic candidates are founded around two core stem cell assets. One is its human retinal progenitor cell line (hRPC). The other is its CTX neural cell line. The Company’s CTX-derived exosome candidate is undergoing development as a novel vector for delivering third party biological drugs.

At present, ReNeuron’s hRPC cell therapy candidate is undergoing evaluation in a continuing Phase I/IIa clinical trial in the United States in subjects with a blindness-causing inherited retinal disease, retinitis pigmentosa (RP). The open-label dose escalation study is being undertaken at two sites to evaluate the safety, tolerability, and preliminary efficacy in subjects with advanced RP - the Massachusetts Eye and Ear Infirmary in Boston, Massachusetts and the Retinal Research Institute in Phoenix, Arizona. In addition, the Company is considering expanding testing of its hRPC cell therapy candidate into subjects with other retinal disorders, such as cone-rod dystrophy (CRD).

ReNeuron’s main strategy is to gain clinical validation for its cell therapy programs by way of well-designed clinical trials in well-regulated territories. The Company ultimately expects to realize value for its technologies and therapeutic programs through out-license to commercial development partners at suitable points in their development.

ReNeuron Group has recently partnered with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. This partnership is for the development, manufacture, as well as commercialization of its hRPC and CTX platforms in the People’s Republic of China (PRC).

New data relating to ReNeuron’s CTX stem cell platform was presented on October 23, 2019 at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a foremost scientific conference, which took place in Barcelona, Spain. Dr Steve Pells, Principal Investigator at ReNeuron, presented new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from ReNeuron’s proprietary, conditionally immortalized, human neural stem cell line (CTX) following re-programming to a pluripotent state.

ReNeuron Group plc (RNUGF), closed Wednesday's trading session at $2.31, up 20.9424%, on 6,500 volume with 6 trades. The average volume for the last 3 months is 274 and the stock's 52-week low/high is $0.569999992/$4.42999982.

chart

Paladin Energy Limited (PALAF)

Penny Stock Tweets, Stock Market Watch, Short Squeeze, Zacks, Marketbeat, Equities, Tech Know Bits, Capital Cube, Morningstar, YCharts, GuruFocus, Teletrader, Wallet Investor, Stockhouse, Nasdaq, Barchart, InvestorsHub, Market Screener, and MarketWatch reported earlier on Paladin Energy Limited (PALAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Paladin Energy Limited develops and operates uranium mines in Australia, North America, and Africa. The Company has two fully built mines in Africa and a portfolio of development assets in Australia and North America. Its value is based on four key drivers - quality pipeline, proven team, industry positioning and sustainability of operations. Incorporated in 1993, Paladin Energy is based in Subiaco, Australia.

The Company is an international uranium leader and proven producer. Paladin Energy serves utilities and other entities mainly situated in the U.S., East Asia, and Western Europe. It has a diversified portfolio of developed mines and projects with unsurpassed uranium price leverage (approximately 8Mlbpa idled capacity). Paladin’s exploration portfolio is large ( greater than320Mlb) and globally diversified.

The Langer Heinrich Mine (LHM) in Namibia is Paladin Energy’s flagship project. It commenced production in 2007. The Langer Heinrich Mine has a production capacity of 5.0Mlb per annum. On May 25, 2018, Paladin received the consent of relevant stakeholders to place LHM into care and maintenance. It stopped presenting ore to the plant. The lead time and capital associated with a re-start to bring Langer Heinrich back into production is less than new projects.

The Kayelekera Mine (KM) in Malawi is Paladin Energy’s second mine. KM was officially opened in April of 2009. It is capable of operating at design production rates of 3.3Mlb U3O8. Because of the sustained low uranium price, it was announced in February of 2014 that processing would stop at Kayelekera and that the site would be placed on care and maintenance. Processing was completed in early May 2014. The expectation is that production will recommence once the uranium price provides a sufficient incentive and grid power supply (ESCOM) is available on site to replace the existing diesel generators.

Paladin Energy holds a 50 percent interest in 69,800 hectares of mineral licences located within the Central Mineral Belt (CMB) of Labrador, Canada. Over the next five years, the Company has the right to increase its interest by 5 percent each year, through funding the exploration and project commitments, increasing its ownership to 75 percent.

Furthermore, the Company has interests in the Isa Uranium Joint Venture (IUJV), the Mount Isa North Project (MINP) and the Valhalla North Project (VNP). These three projects include 10 deposits containing 148.3Mlb U3O8 across all resource categories. The majority of the mineralization (76.3Mlb) is concentrated in the Valhalla deposit.

Additionally, Paladin Energy has a 100 percent interest in the Manyingee Project. This is a sandstone hosted uranium project comprising 41Mlb U3O8 across two deposits. In 1985 a field leach trial (FLT) was conducted at the Manyingee deposit. It showed the deposit is amenable to extraction via in-situ recovery (ISR). Nonetheless, development didn't proceed at the time because of the depressed uranium market. The Company’s belief is that Manyingee can be developed into an in-situ recovery (ISR) uranium mining operation over a period of four to five years.

Paladin Energy Limited (PALAF), closed Wednesday's trading session at $0.0715, up 7.4703%, on 2,510 volume with 18 trades. The average volume for the last 3 months is 134,429 and the stock's 52-week low/high is $0.054999999/$0.144999995.

chart

TechCare Corp. (TECR)

InvestorsHub, MarketWatch, Stockhouse, OTC Markets, Investing, 4-Traders, GuruFocus, Morningstar, YCharts, Penny Stock Tweets, PR Newswire, Investors Hangout, Seeking Alpha, Wallet Investor, Stockwatch, Barchart, last10k, Dividend Investor, Emerging Growth, and Market Screener reported earlier on TechCare Corp. (TECR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

TechCare Corp. has an inventive delivery platform that utilizes vapor technology for natural health and beauty treatments. The Company engages in the design, development, and commercialization of this unique delivery platform using vaporization of different natural, plant-based compounds, to enable a wide variety of treatment solutions. A technology company and OTCQB-listed, TechCare is based in New York City.

The Company has a strategic partnership agreement with HoMedics, one of the world's leading brands in health and wellness products. HoMedics manufactures, markets, and distributes TechCare's Novokid products in the United States, Canada, Brazil, Argentina, Colombia, and Costa Rica. These products are co-branded as HoMedics products powered by TechCare.

Novokid consists of a portable device that vaporizes TechCare's all-natural, plant-based solution contained in a disposable capsule. It comes with a proprietary head cap. Novokid is 100 percent natural, plant-based and pesticide-free. Novokid is the first of its type home use device. It presents a scientifically proven solution to eliminate lice, super lice, as well as eggs.

Novokid uses a proprietary vapor-based delivery platform. TechCare’s Novokid has received CE Mark approval as a CLASS I Medical Device. Novokid uses a simple 10-minute dry treatment. The treatment requires no rinsing or washing and is fast, dry, and clean. It is easily administered at home or while mobile. In addition, Novokid can be used as a maintenance and preventative treatment if used regularly.

The Company’s Shine is a hair treatment device. It underwent development with globally renowned industry leaders. Shine cleanses the hair and scalp. It also rejuvenates hair by returning its natural health, shine, body and luster. The expectation is that Shine will launch later in 2019.

TechCare announced in May of 2018 that following intensive research and development (R&D) and investments, it expanded its existing Intellectual Property (IP) portfolio with a previously submitted patent application of its Smart Capsule™ technology. Building upon its existing patents and knowledge, the new Smart Capsule™ technology enables the vaporization of two or more compounds simultaneously. As a result, this expands the range of applications while yielding superior performance, usability and ease-of-use.

Recently, TechCare announced that on January 21, 2019, it entered into a joint venture (JV) contract with China-Israel Biological Technology Co. Ltd. (CIB). With this agreement, TechCare's subsidiary Novomic Ltd. and CIB agreed to create a Chinese JV company in China.

The JV will concentrate on the field of health and cosmetics, including medical care, home care, hair care, and body and skin care, to develop a comprehensive and extensive range of health, wellness, beauty and home products for customers by using TechCare's patented technology of vaporization of natural and plant-based compounds. The JV’s intention is to sell its products in the Greater China region, including mainland China, Hong Kong, Macao and Taiwan, directly or through others.

TechCare Corp. (TECR), closed Wednesday's trading session at $0.031, up 2.649%, on 100 volume with 4 trades. The stock's 52-week low/high is $0.011099999/$0.384000003.

chart

Medifocus, Inc. (MDFZF)

MoneyHub, OTC Markets, Wallet Investor, SmallCapVoice, Investor Place, Investor Network, Barchart, Street Insider, Financial Content, Trading View, MarketWatch, and otc.Watch reported beforehand on Medifocus, Inc. (MDFZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medifocus, Inc. has a portfolio of medical technologies that use patented  Focal Thermal Technology  to treat conditions ranging from Prostate Diseases to Breast Cancer. The Company’s portfolio of medical products includes thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer. OTCQB-listed, Medifocus is based in Columbia, Maryland.

The Company owns two technology platforms with approximately 100 issued and pending U.S. and worldwide patents. One platform is the “Endo-thermotherapy Platform”. The other platform is the “Adaptive Phased Array Microwave Focusing Platform”.

Based on these proprietary technology platforms, Medifocus has developed two advanced therapeutic products. One is the Prolieve® system for the treatment of BPH. The other is the Adaptive Phased Array (APA)-1000 system for the treatment of breast cancer.

The Prolieve® Thermodilatation™ System provides symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) via a simple, 45-minute, in-office treatment. Prolieve® is Food and Drug Administration (FDA) and Medicare approved for treating symptomatic BPH with more than 100,000 cases performed in the U.S. alone, and with proven long-term safety, efficacy, and durability. The purpose of the Prolieve system is to provide a relatively painless and effective alternative to drug therapy, and also certain types of surgical procedures to treat the symptoms of BPH.

Medifocus’ Heat Activated Gene Therapy, exclusively licensed from Duke University, aims at using the Company’s Focal Thermal Technology to enhance selective expression of therapeutic genes injected intratumorally to optimize cancer cell killing while lessening systemic side effects.

The APA 1000 Breast Cancer Treatment System developed by the Massachusetts Institute of Technology (MIT) has been shown in Phase 2 clinical trials to offer substantial additional shrinkage of the sizes of breast cancer in combined ChemoThermal therapy versus Chemotherapy alone. Additionally, it was shown to be effective in reducing margin positivity when patients were treated with APA 1000 before lumpectomy.

Recently, Medifocus announced that its Prolieve® Thermodilatation™ procedure for the treatment of BPH have been performed and reimbursed by insurance carriers in Hong Kong.

Dr. William Jow, said, “We are pleased that our efforts, together with the contribution from our Asian partners, are starting to yield tangible financial results from Prolieve® sales. Through our resolution in promoting Prolieve® in Asia and after having presented at three major international conferences within the past 16 months, I would like to see Prolieve® sales start to pick up in the near future both domestically and internationally. We are pleased to enter the fast-growing Asia markets where BPH and cancers of the prostate and breast are quickly becoming major public health concerns.”

Medifocus, Inc. (MDFZF), closed Wednesday's trading session at $0.006, up 80.1802%, on 375 volume with 1 trade. The average volume for the last 3 months is 12,693 and the stock's 52-week low/high is $0.001099999/$0.0284.

chart

BioVie, Inc. (BIVI)

NetworkNewsWire, Penny Stock Tweets, Stockhouse, Investor Place, Wallmine, Wealth Insider Alert, InvestorsHub, Morningstar, YCharts, EuroInvestor, MarketWatch, GuruFocus, Street Insider, and Simply Wall St reported earlier on BioVie, Inc. (BIVI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. focuses on the discovery, development, and commercialization of unique drug therapies for liver disease. At present,  the clinical-stage Company is centering on commercializing BIV201. This is a novel approach to the treatment of ascites due to chronic liver cirrhosis. OTCQB-listed, BioVie has its corporate headquarters in Beverly, Massachusetts.

The Company states that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering BioVie’s new drug candidate BIV201. 

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a major unmet medical need. The Food and Drug Administration (FDA) has never approved any drug specifically for treating ascites.

BIV201 is a continuous infusion of the peptide terlipressin, first undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in about 40 nations for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the United States.

BioVie announced in April 2017 that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 could begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites due to advanced liver cirrhosis. BioVie also announced in April 2017 the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis.

The FDA has granted Fast Track designation for BIV201 (continuous infusion terlipressin), BioVie’s patented Orphan drug candidate. BIV201 is currently undergoing evaluation for the treatment of refractory ascites because of liver cirrhosis in a mid-stage (Phase 2a) U.S. clinical trial.

The FDA has granted Orphan Drug designation to BioVie for terlipressin for the treatment of hepatorenal syndrome (HRS). BioVie earlier secured an Orphan Drug designation for terlipressin for treating ascites. The Company is exploring additional Orphan designation opportunities.

Recently, BioVie announced that it completed enrollment in a Phase 2a open-label clinical study of BIV201 (continuous infusion terlipressin) in patients with refractory ascites because of advanced liver cirrhosis.

Patrick Yeramian, MD, BioVie’s Chief Medical Officer, said, “We are pleased to have achieved this important clinical milestone as we continue to develop BIV201 for patients with refractory ascites who are at high risk of deadly complications. What we have learned from this initial study is informing our next clinical trial design. The results will be presented to the FDA in the first half of 2019 and we expect to receive guidance on the BIV201 clinical development plan.”

BioVie, Inc. (BIVI), closed Wednesday's trading session at $4.50, up 50.00%, on 100 volume with 13 trades. The average volume for the last 3 months is 834 and the stock's 52-week low/high is $2.79999995/$7.39375019.

chart

Alltemp, Inc. (LTMP)

MissionIR, Stock Communications Group, Dividend Investor, 4-Traders, InvestorsHub, GuruFocus, The Street, Investors Hangout, Barchart, StockInvest, MarketWatch, Stockhouse, Morningstar, Wallet Investor, Market Screener, and Capital Cube reported earlier on Alltemp, Inc. (LTMP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alltemp, Inc. is a developer of proprietary, environmentally-friendly, refrigerant technologies. The Company has developed a proprietary refrigerant technology, called alltemp®. This is a proven replacement for many global refrigerants that have adversely affected the worldwide environment.  Alltemp is based in Westlake Village, California.

alltemp®’s refrigerants are for the commercial and residential markets. alltemp® is the Company’s solution for the replacement of R-407c, R-134a, R-404a, and HCFC-22, known as R-22, but which is quickly being phased out in all developed nations because of environmental concerns over its strong effect on the depletion of the Earth's ozone layer.  

alltemp® refrigerants have broad applications. These range from Heating Ventilation and Air Conditioning (HVAC), to refrigeration and foam insulation, to industrial solvents. alltemp® solutions provide a sustainable, eco-friendly, true drop-in refrigerant. It meets the Montreal/Kyoto Protocols and EPA  (Environmental Protection Agency) standards with the lowest Global Warming Potential for any non-flammable HFC. alltemp®  yields a 27 percent average decrease in kWh,  without loss in capacity.

Alltemp successfully completed two years of early adopter testing of its alltemp® refrigerant at several Fortune 100 companies' facilities for its Montreal and Kyoto Protocol compliant refrigerant. Furthermore, test results revealed that alltemp® yielded significant average savings in energy consumption. This is while maintaining capacity.

Alltemp announced in January 2018 that it released a new refrigerant alternative for R-404A applications called alltemp® 4. This is a drop-in refrigerant. R-404A has one of the highest GWPs (Global Warming Potential) of any HFC refrigerants. It is quickly being phased out in the European Union (EU) and other developed countries.

Alltemp announced in March 2018 that flashpoint chamber testing conducted by DEKRA Insight confirmed that alltemp® refrigerant has zero flammability. A minimum of 20 different chamber tests in the liquid phase and 20 vapor phase tests, with temperatures as high as 60º C = 140º F, revealed zero flammability and no ignition with alltemp® refrigerant.

Alltemp has its R-410A replacement refrigerant, designated alltemp® H. Like the Company’s other refrigerants, alltemp® H is engineered to use the same anti-corrosive and non-flammable alltemp® core technology that provides major energy efficiencies and meets ASHRAE A1 safety classification standards.

R-410A was designed to replace R-22, which has a substantial environmental impact and Ozone Depletion Potential (ODP). The lower the GWP value, the better the refrigerant is for the environment. R-410A has a Global Warming Potential (GWP) rating of 2,088. Its predecessor R-22 has a GWP rating of 1700.

Alltemp, Inc. (LTMP), closed Wednesday's trading session at $0.0689, up 25.2727%, on 4,550 volume with 7 trades. The average volume for the last 3 months is 45,017 and the stock's 52-week low/high is $0.029999999/$0.090000003.

chart

SETO Holdings, Inc. (SETO)

Penny Stock Tweets, OTC Markets, 4-Traders, WalletInvestor, InvestorsHub, and Stockhouse reported on SETO Holdings, Inc. (SETO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A development stage company, SETO Holdings, Inc. provides healthcare services. Based in Hanover, Maryland, the Company focuses on three main sectors. These are Health, Education and Clean Energy.

SETO analyzes markets, operations, and guides businesses through the challenges they face. Regarding Healthcare, the Company provides hearing health care and distributes hearing aids via 15 hearing clinics in Maryland and Virginia. Established in 2004, SETO lists on the OTC Markets.

Advanced Hearing Group is the Company’s principal audiology and hearing Services Company. Advanced Hearing Group has clinics across the U.S. Mid-Atlantic region. Seto's Health (SH) division works to expand the Company’s other health services.

Seto Energy (SAE) promotes alternative energy projects in India. In addition, Seto's Education (SE) division promotes health education to the 50-plus active adult community Seto Life (SL).

SETO is working to expand its existing healthcare services within the U.S. The Company is pursuing the implementation of projects in developing markets, particularly in India. Concerning Clean Energy, SETO is expanding its operations to encompass clean energy in developing markets, again specifically in India.

In January of this year, SETO Holdings announced that its subsidiary entered the cannabis sector, specifically the $US15 billion medical marijuana sector. This represents a significant expansion within the Company's Health Division.

SETO’s plan is to execute Hydroponic farming techniques for the development of cannabis farming and for the development of products derived from medical marijuana cultivation. Additionally, the Company plans to implement financial technology solutions for the fast expanding, multi-billion-dollar cannabis sector.

Recently, SETO Holdings announced its newest hearing clinic in Frederick, Maryland. This clinic will center on pediatric and geriatric patients. This also boosts Seto Hearing Group's (SHG) presence in the market. SETO has partnered with the Department of Aging as the exclusive hearing care provider for its 20 facilities in Baltimore County, Maryland.

SETO Holdings also recently announced it will start the development of medical software. This project is being developed under a subsidiary called Setosoft. Setosoft's software applications will augment the Company’s internal efficiencies and that of other healthcare providers. The design phase has been completed. Setosoft is putting together the team of software engineers to implement the project.

SETO Holdings, Inc. (SETO), closed Wednesday's trading session at $0.03804, up 35.3737%, on 82,000 volume with 1 trade. The average volume for the last 3 months is 25,045 and the stock's 52-week low/high is $0.021099999/$0.079999998.

chart

Tiger Reef, Inc. (TGRR)

Investors Hub and MarketWatch reported on Tiger Reef, Inc. (TGRR), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Tiger Reef, Inc. is a diversified producer of ultra premium rums under the Tiger Reef® brand. Also, the Company is a developer of casual dining restaurant properties in the Caribbean under the Mermaid Reef Ocean Grill & Lounge™ brand. The Company formerly went by the name Blue Water Bar & Grill, Inc. It changed its corporate name to Tiger Reef, Inc. in October 2016. 

The Company is a subsidiary of BWG Investments & Development, Ltd. Tiger Reef’s shares trade on the OTC Markets’ OTCQB. Tiger Reef is based in Cole Bay, the Netherlands Antilles.

Tiger Reef has established a new wholly-owned operating subsidiary in St. Maarten, Dutch West Indies under the name Mermaid Reef, B.V.  Mermaid Reef will own and operate the initial Mermaid Reef Ocean Grill & Lounge™ in St. Maarten. 

In May 2017, Tiger Reef announced that its wholly-owned subsidiary, Tiger Reef Spirits, Ltd., entered into a Letter of Intent  (LOI)  with International Spirits & Beverage Group, Inc. (ISBG). ISBG is a Nevada based alcoholic beverage company. It specializes in the development, marketing,  and global sales of innovative wine and spirits brands.

ISBG will assist Tiger Reef with obtaining U.S. regulatory approval for the complete line of Tiger Reef® ultra premium rums. In addition, ISBG will become the U.S. importer of record for Tiger Reef’s complete line of rums.

The Mermaid Reef Ocean Grill & Lounge™ was being developed at Simpson Bay Resort & Marina on the island of St. Maarten, Dutch West Indies. Key elements of the Restaurant floor plan included the restaurant encompassing 2,466 sq. ft. of indoor and outdoor waterfront space.

In October of 2017, Tiger Reef issued its first statement and shareholder update since the Company’s St. Maarten headquarters experienced a direct hit from Hurricane Irma during the early morning hours on September 6, 2017. Tiger Reef’s office headquarters suffered catastrophic damage during the Hurricane Irma storm.

All of the Company’s office equipment, computers, paper files, and more were damaged beyond repair during the storm. However, electronic files were backed up offsite and were recovered. Tiger Reef was renovating a leased waterfront restaurant space in the Simpson Bay Resort & Marina in preparation of opening the first Mermaid Reef Ocean Grill & Lounge™ in time for the 2017 tourist season. In addition, Simpson Bay Resort & Marina and the Company’s restaurant location suffered massive damage and flooding.

Tiger Reef and Simpson Bay Resorts & Marina Management had numerous discussions since the storm concerning the future of the resort and restaurant. Based on the fact that the resort would be closed for a minimum of six months, but probably longer, and other uncertainties, Tiger Reef and Simpson Bay Resorts & Marina mutually agreed to terminate the lease agreement for the restaurant space. Tiger Reef will make a one-time write-off or its lost investment in this restaurant property.

Tiger Reef temporarily suspended all efforts related to the Mermaid Reef Ocean Grill & Lounge™ brand. The Company said this past October that it would re-evaluate its options for the brand in the coming months after it recovers from the losses incurred due to Hurricane Irma.

Tiger Reef, Inc. (TGRR), closed Wednesday's trading session at $0.0002, even for the day, on 5,050 volume with 6 trades. The average volume for the last 3 months is 4,676,328 and the stock's 52-week low/high is $0.000099999/$0.005499999.

chart

The QualityStocks Company Corner

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Drug product consumption innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced a trade agreement that continues to advance the company’s revenue-building efforts through licensing its technology to other product manufacturers that can benefit from Lexaria’s DehydraTECH™ oral drug delivery IP. Also today, the company was highlighted in a publication from HempWireNews, examining how the American hemp industry has seen a lot of upheavals since the 2018 Farm Bill legalized industrial hemp and gave farmers all over the country leeway to grow the cash crop. In the year that followed, the sector grew by leaps and bounds. However, it was barely regulated, and farmers, processors and other players were having a hard time running their operations. Additionally, LXRP announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips' cannabis products, both in its current California market and across the United States. To view the full press release, visit http://cnw.fm/4qN9T.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Wednesday's trading session at $0.51, up 6.9855%, on 31,787 volume with 86 trades. The average volume for the last 3 months is 119,796 and the stock's 52-week low/high is $0.3037/$1.57000005.

Recent News

chart

No Borders Inc. (OTC: NBDR)

The QualityStocks Daily Newsletter would like to spotlight No Borders Inc. (NBDR).

No Borders Inc. (OTC: NBDR) was featured today in the 420 with CNW by CannabisNewsWire. On Friday evening, the Missouri Department of Health and Senior Services was ordered by a court in Missouri to delay the approval or rejection of one applicant who had applied for a license to run a medical marijuana dispensary. According to the statement previously issued by the Health Department, the permits would enable businesses located in secure areas to sell medical cannabis to patients.

No Borders Inc. (OTCQB: NBDR) specializes in the acquisition, creation and scaling of commercial products by utilizing cutting-edge technologies designed to reduce costs while increasing revenues and shareholder value. With active subsidiaries in healthcare, education, cannabidiol (CBD), finance and technology, No Borders is uniquely positioned to use its expertise to improve margins and add business lines within target verticals. No Borders is headquartered in Arizona with remote work resources in the U.S., South America, Asia and Europe.

Different by Design

Deeply experienced at actionable data compilation, analysis and utilization, No Borders believes that data utilization in a Web 3 ecosystem of predictive analytics, blockchains, consensus algorithms, IoT and 5G are vital keys to the future of disrupting global business.

The company leverages its technological talent and visionary approach alongside best-in-class branding, messaging and product teams to simultaneously deploy multiple vertical product offerings at the same time.

With resources around the world, No Borders operates as a 100% remote work, lean operating organization with a founding ideological focus on “Lifestyle by Design.” No Borders’ teams are built by allowing people to work when they want and from where they want as long as deliverables and results are achieved. This structure allows for strategic talent acquisition without the need for relocation or commuting; lowered operating and fixed costs; as well as improved morale and substantially increased staff productivity.

NBDR Companies

  • No Borders Dental Resources Inc. provides equipment and supplies to medical and dental professionals across the U.S. through the trade name, MediDent Supplies. MediDent has a strategic focus on expanding product portfolios and optimizing lifetime customer value while minimizing customer acquisition cost in the medical, dental and veterinary spaces.
  • No Borders Naturals is a purveyor of health and wellness products for active consumers and their pets. No Borders Naturals aims to be an industry leader in alternative wellness product offerings and is currently expanding its digital offering with impactful product up-sell opportunities such as a series of “Buy Two-Get One” on products on its 1000mg CBD tincture, collagen and retinol beauty cream.
  • No Borders Labs Inc. provides leading-edge tech tools to the No Borders family of companies along with building, testing and deploying technology solutions and products to the market while also offering consulting, architecture and software development services to external businesses looking to update their technology infrastructure for greater efficiency, security and transparency.
  • No Borders Funding Inc. provides internal capital and strategic funding options for the family of No Borders companies while actively engaging and networking to find, acquire, structure and deploy unique financial products, solutions and systems with traditional, distributed ledger and blockchain technologies.
  • No Borders Education Inc. provides internal staff training and strategic education tools for the No Borders family of companies while pursuing external revenue generating educational opportunities within the verticals for which No Borders deploys products, services or technologies.

 

Leadership

No Borders CEO Joseph Snyder is a serial entrepreneur whose experiences in real estate investment, financial services and digital strategy over the last 15 years provide a strong, grounded foundation for the structure and ideas outlined in the company’s strategic plan. He brings a unique set of long-term business experiences that provide No Borders with a clear “mile-high” view of the intricately linked systems and challenges associated with growing and scaling our vision.

COO Cynthia Tanabe, a licensed real estate agent/broker since 2004, has successfully built a highly respected investor and bank-focused real estate and property management firm in Arizona with tens of millions of dollars of properties owned and sold.

CTO Chris Brown has 14 years of experience in the IT industry ranging from full stack programming, hardware support, engineering and maintenance, to enterprise-level information system analysis, design, development and implementation. From his background in Air Force intelligence to earning dual B.S. degrees in computational mathematics and biochemistry from Arizona State University, Brown has been engrossed with technologies such as artificial intelligence, machine learning, and decentralized blockchain ledger systems and their connections with real world business applications.

Management is backed by an advisory board with a diverse range of expertise blockchain, brand development, specialty retail, branded consumer products, technology, marketing and other specialties pertinent to No Borders’ growth strategy.

No Borders Inc. (NBDR), closed Wednesday's trading session at $0.014, up 0.719424%, on 8,659 volume with 7 trades. The average volume for the last 3 months is 99,370 and the stock's 52-week low/high is $0.007699999/$0.048799999.

Recent News

chart

InsuraGuest Inc.

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Inc..

InsuraGuest Inc. Guest Protection Insurance Coverage was featured today in a report from NetworkNewsWire looking at how a fall that Grammy Award-winning rock singer and actor Meat Loaf suffered last year and the resulting lawsuit against the Hyatt Regency Hotel in Texas (http://nnw.fm/6Zi8t) serve as a high-profile example of the risks convenience service industries accept when they welcome guests, as well as the risks guests may face when they choose to stay at an establishment.

InsuraGuest Inc. is a SaaS (Software-as-a-Service) company utilizing its proprietary flagship InsurTech software platform to provide specialized insurance products to end users in the business-to-business (B2B) and business-to-consumer (B2C) markets. The company’s first focus is on the B2B hotels and vacation rentals sectors, where its API integrates with the clients’ property management systems to offer guests a specialized guest protection policy. The platform and policy combination “InsurTech” product helps transfer the exposure to liability away from the client/property while guests benefit from potential accident and loss coverage during their stay.

InsuraGuest’s platform is currently capable of integrating with approximately 70 different hotel and vacation rental property management systems, giving it access to roughly 40,000 properties worldwide.

The company continues to pursue expansion opportunities and recently signed a Letter of Intent with a master general agent in the United Kingdom and Europe to distribute its platform and products to hotel and vacation rental markets in those regions, as well as plans to expand to Asia in 2020.

Protecting Guests, Enhancing Customer Experience

InsuraGuest is the first line of defense for both the property and the guest.

InsuraGuest is purchased by the hotel or vacation rental “property,” which offers the policy to each registered guest and its occupants for an additional fee. The specialized policy affords coverage for theft of personal property while in the hotel, as well as accidental medical expense and accidental death and dismemberment, up to the policy limits of $2,500 to $50,000.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United State alone, where there are approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s demographics combined will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Specialized Guest Protection Policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Business Highlights

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a BS undergraduate degree in Consumer Studies with an emphasis in Architecture as an undergraduate at the University of Utah. He subsequently earned his Master’s in Business Administration. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends.

Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Christopher J. Panos Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018. He also has served as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.


Recent News

chart

Jerrick Media Holdings, Inc. (OTC: JMDA)

The QualityStocks Daily Newsletter would like to spotlight Jerrick Media Holdings, Inc. (OTC: JMDA).

Jerrick Media Holdings (OTCQB: JMDA), a holding company that gives technology products the resources and opportunities to make ideas a reality, today announced the launch of Challenges on its proprietary long-form digital publishing platform Vocal. Through friendly competition, Challenges are intended to inspire new brands and creators to join the Vocal community. Multiple Challenges across a range of topics will be offered each month for creators to participate in for the chance to win cash prizes, experiences, and more. To view the full press release, visit http://nnw.fm/sG8sV

Jerrick Media Holdings, Inc. (OTC: JMDA) develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience.

Jerrick’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity.

Vocal

Designed to develop and cost-effectively engage content creators, the Vocal platform enables its over 500,000 registered content creators to reach an engaged audience and monetize their content. In addition to providing relevant content, Vocal’s technology is centered on efficiency and scalability through its niche digital communities, as well as output through its data-driven distribution strategy.

Vocal partners with content creators and brands that recognize difficulties inherent in the digital advertising space and that can benefit from branded content marketing opportunities available on publishing platforms like Vocal.

All content available on Vocal is created within the platform’s custom editor and published on one of Vocal’s embedded genre-specific communities, spanning topics that range from food to wellness, beauty, technology and more.

In May 2019, Jerrick launched Vocal+, its premium subscription membership program. Vocal+ members pay a membership fee for premium value-added features, including receiving increased earnings for their content, reduced platform processing fees for tips received, a Vocal+ badge on their creator page, access to new features on the Vocal Platform, and other rewards. Creators can sign up for free or upgrade to Vocal+, available for purchase on either an annual or monthly subscription basis.

 

Vocal for Brands

Vocal for Brands is an in-house creative studio that generates actionable data from bespoke native advertising campaigns. Vocal for Brands partners with direct-to-consumer (DTC) to create beautiful, campaign-optimized stories on Vocal that build brand affinity, trust and drive results.

Additionally, Jerrick provides a Managed Services offering to business-to-business (B2B) and business-to-consumer (B2C) product and service brands which encompasses a full range of digital marketing and e-commerce solutions. Managed Services includes the setup and ongoing maintenance of clients’ websites, Amazon and Shopify storefronts and listings, social media pages, search engine marketing, and other various tools and sales channels utilized by e-commerce sellers for sales and growth optimization. In addition to partnering with Managed Services clients, the company offers a range of la carte services.

Growth Strategy

Upon the consummation of its anticipated listing on the Nasdaq Capital Market, Jerrick intends to change its official company name to “Creatd, Inc.,” subject to stockholder approval.

This rebranding will initiate Jerrick’s go-forward growth strategy and its plans to expand its offerings and provide technology products and resources for creators to help transform their ideas into reality. The strategic plan is designed to greatly increase Jerrick’s potential market value via a plethora of new revenue streams.

Creatd will focus on a community of creators that number more than 2.5 billion users, for which it will offer democratized, transparent platforms for distribution, sentiment, resources and monetization. The company’s agile development process will rely on a combination of bleeding-edge technology that eliminates barriers and creates efficiencies. Superior design thinking and data analysis will allow Creatd to expand its digital footprint to a global community.

Creatd will partner with a community of technology collaborators and sophisticated investors who collaborate to provide technology solutions for creators, brands and their respective audiences. The company’s solutions, business processes, technology platforms and design theories will lend themselves to application opportunities on a global scale.

History & Management

Jerrick was founded in 2012. Initially a private media company providing online content through a portfolio of brands, Jerrick’s needs quickly outpaced its initial technology and product offering. In 2015, Jerrick partnered with Thinkmill, a premiere, Australia-based product design and development group to create a content management system (CMS) for its brands; that system evolved into the company’s flagship product, Vocal.

Today, Jerrick’s management team is an impressive group of abstract thinkers united by their passion to solve problems. Leading the team are founder and CEO Jeremy Frommer, and Justin Maury, Jerrick’s president and head of product.

Frommer’s career includes two decades in the financial technology industry, working as a hedge fund and portfolio manager, as well as on the sell-side of the financial industry. Frommer started NextGen Trading, a software development company building proprietary equity trading platforms. NextGen was acquired by Carlin Financial Group of which Frommer became CEO. RBC Capital Markets Corporation eventually bought Carlin. At RBC, Frommer was managing director, head of the Global Prime Services group and a member of the RBC Global Equities Operating Committee.

Maury joined Jerrick in 2013, bringing with him 10 years of experience in the creative industry. Since partnering with Frommer to establish Jerrick, Maury led the company’s product development for more than four years. His passion for the creative arts and technology ultimately yielded the vision for Vocal. During the Jerrick’s early formative years, Maury was a driving force in creating the vision, design and architecture for the Vocal platform and managing the oversight of technology development.

Jerrick Media Holdings, Inc. (JMDA), closed Wednesday's trading session at $4.00, even for the day, on 1,234 volume with 1 trade. The average volume for the last 3 months is 1,368 and the stock's 52-week low/high is $1.63999998/$5.00.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com (CIIX) was featured today in a publication from CBDWire, examining how cannabidiol, or CBD, has been having a fantastic run for the last few years. For something that was barely known three or so years ago, it has grown into an industry worth millions of dollars, and experts say it may hit $20 billion by 2020. It’s quickly losing its fringe product status and moving into the mainstream, as evidenced by the mountains of anecdotal evidence detailing its diverse medical abilities.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Wednesday's trading session at $0.175, even for the day, on 1,700 volume with 19 trades. The average volume for the last 3 months is 54,717 and the stock's 52-week low/high is $0.150000005/$0.550000011.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

In an exclusive interview at the LD Micro Main Event 2019, SRAX Inc. (NASDAQ: SRAX) Founder and CEO Christopher Miglino discussed how SRAX has revolutionized consumer data collection through BIGtoken, its proprietary, secure and transparent platform. The platform enables consumers to own and monetize their data as they earn rewards when they opt into the data sharing, as well as each time their data is purchased and each time they bring a new user to the platform.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Wednesday's trading session at $2.31, off by 3.3473%, on 220,206 volume with 225 trades. The average volume for the last 3 months is 124,175 and the stock's 52-week low/high is $1.04999995/$5.8499999.

Recent News

chart

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

A new study has revealed a significant increase in the use of large-scale additive manufacturing technology, also called 3D printing. Essentium, a Texas-based innovator in industrial additive-manufacturing platforms and filament materials, released the study and marks 2020 as the year when additive manufacturing at scale transforms manufacturing across a number of sectors, With multiple manufacturers across various sectors poised to embrace 3D printing at scale in 2020, Sigma Labs Inc. (NASDAQ: SGLB) aims to exploit this rapidly growing market opportunity with its revolutionary technology that enables in-process quality assurance of 3D-metal-printed parts. Sigma Labs is at the epicenter of the explosive additive manufacturing market growth as the leading provider of third-party in-process quality-assurance software for the commercial 3D metal printing industry.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Wednesday's trading session at $0.93, off by 1.0638%, on 3,810,696 volume with 200 trades. The average volume for the last 3 months is 198,517 and the stock's 52-week low/high is $0.451099991/$2.45000004.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ: GNPX) was highlighted today in a publication from Financialnewsmedia.com, examining how pancreatic cancer is a notoriously aggressive and hard-to-treat malignancy; the five-year survival rate is less than 10%. Treatment options for pancreatic cancer are limited to surgery, radiation, and chemotherapies; thus, demand is high for safer, more-efficacious drugs, which will serve to drive the market.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $1.89, up 64.3478%, on 85,973,789 volume with 109,470 trades. The average volume for the last 3 months is 1,550,663 and the stock's 52-week low/high is $0.231000006/$2.25999999.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was highlighted in a publication from Financialnewsmedia.com, examining the forward vectors of the Cannabis market.  

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Wednesday's trading session at $0.30365, up 8.4464%, on 64,049 volume with 176 trades. The average volume for the last 3 months is 165,270 and the stock's 52-week low/high is $0.139899998/$0.930000007.

Recent News

chart

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)

The QualityStocks Daily Newsletter would like to spotlight Blue Hat Interactive Entertainment Technology (BHAT).

Blue Hat Interactive Entertainment Technology ("Blue Hat" or the "Company") (NASDAQ: BHAT), a producer, developer and operator of augmented reality interactive entertainment games, toys and educational materials in China, today announced the dismissal of Friedman LLP ("Friedman") as the Company's independent registered public accounting firm and the appointment of JLKZ CPA LLP ("JLKZ") as the Company's independent registered public accounting firm, effective as of the same date.

Blue Hat Interactive Entertainment Technology (BHAT) is a cutting-edge creator, developer and operator of popular augmented reality (“AR”) interactive smart toys and educational games in China. Blue Hat’s mobile-connected entertainment platform connects physical items to mobile devices through wireless technologies, creating a unique interactive user experience in various mobile games, interactive educational materials and toys with mobile game features.

Blue Hat designs original toys and games that utilize augmented reality technology, motion capture technology, image recognition technology, voice control, light sense technology, infrared, levitation induction, and other trending scientific technologies to transverse the virtual with reality. Blue Hat creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. This combination provides users with a more natural form of human computer interaction, enhances a user’s perception of reality, and delivers a more immersive entertainment experience.

Proprietary Technology

Founded in 2010, Blue Hat’s proprietary technology, product research and development, marketing channels and brand operation are the cornerstones of the business. Blue Hat focuses on the combination of “online” and “offline” activity and the interaction between “entertainment” and “product” to create a high-tech entertainment platform combining mobile games and AR. With the help of computer graphics, motion capture technology, image recognition technology and visualization technologies, Blue Hat accurately “places” virtual objects into the physical world, creating a new and stimulating visual environment for users.

Blue Hat recently displayed a variety of its sci-tech products at the Guangzhou International Toy Exhibition in China including AR Racer, Elastic Bubbles, AR Space Track, AR Alloy Toy Car, AR Need a Spanking, 5D Animated Magic Aquarium, Bug Travelers, AR Picture Book and other interactive games and smart toys.

The company has multiple products in development including new generations of four primary product lines and two new product lines.

Patents and Copyrights

Blue Hat’s advanced AR technology in interactive entertainment is protected by 178 authorized patents with 44 patents in various stages of the application process.

Another 14 applications for Patent Cooperation Treaty, or PCT, have been filed for international patents. As of March 31, 2019, the company owns 645 copyrights for artwork, 71 registered trademarks and 27 software copyrights.

Sales and Marketing

There has been rapid growth in the toys and games industry in China over the last several years. Total retail sales of toys and games in China soared from RMB 111.8 billion in 2012 to RMB 276.5 billion in 2017 with an average annual growth rate of 19.9% in 2017. Blue Hat believes the company is well positioned with little competition as the toy industry rapidly shifts toward intelligent and interactive toys and games. Retail sales of electronic toys grew at 24% annually in 2017 while that of traditional toys grew at 7%.

In addition to a powerful ecommerce presence, Blue Hat has long-term relationships with partnered distributors that place the company’s AR interactive entertainment products into well-known international retail chains and retail outlets. Blue Hat’s integrated online and offline sales channels include e-commerce giants such as Amazon and Alibaba, retail chain stores and the company’s physical experience store located in Xiamen, China. Blue Hat plans to open or franchise approximately 100 additional stores in China by 2021.

Blue Hat’s community-based platform offers users a highly engaged and interactive community with online communication forums and offline social activities. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction. This novel educational experience helps realize optimal transformation of information, creating a knowledge and enhancing cognition.

Management

Director and CEO Xiaodong (Sean) Chen has over 20 years of experience creating, developing and producing toys and games related products. Chen earned his EMBA from Renmin University of China and has been chairman of the board of directors and general manager of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

CFO and Director Caifan, who has over 20 years of financial accounting and taxation experience, earned a degree in finance from Hunan University of Finance and Economics. He has served as director, deputy general manager and financial controller of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

Jianyong Cai, chief technology officer and director, has over 35 years of experience in data communication principles, communication network foundation, software engineering, communication network theory and technology and computer network architecture. He holds degrees in data communication principles, communication network foundation and software engineering from University of Science and Technology of China. He has been director, deputy general manager and chief engineer of Fujian Blue Hat Interactive Entertainment Technology Ltd. since January 2010.

Blue Hat Interactive Entertainment Technology (BHAT), closed Wednesday's trading session at $1.72, off by 4.9724%, on 18,755 volume with 127 trades. The average volume for the last 3 months is 81,717 and the stock's 52-week low/high is $1.72000002/$6.25.

Recent News

chart

Grapefruit Boulevard Investments Inc. (IGNG)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit Boulevard Investments Inc., the wholly owned subsidiary of Imaging3 Inc. (IGNG).

Grapefruit Boulevard Investments (“GBI”), a licensed and fully compliant California based cannabis distribution and manufacturing company and a wholly owned subsidiary of Imaging3, Inc. (OTCQB: IGNG) (collectively “Grapefruit”), this morning announced that it has filed Amendment No. 1 to its Registration Statement on Form S-1 that was originally filed on July 28, 2019 regarding conversions of convertible notes issued to the company’s institutional investor Auctus Fund, LLC. To view the full press release, visit http://cnw.fm/DEBv5.

Grapefruit Boulevard Investments Inc., a California corporation (“Grapefruit”), as of May 31, 2019, is a wholly owned subsidiary of Imaging3 Inc. (OTC: IGNG), a Delaware corporation whose shares of $.001 par value common stock are publicly traded on the OTCMarkets OTCQB Market under the symbol “IGNG.” IGNG is subject to the reporting requirements of the Securities Exchange Act of 1934 and files annual and quarterly reports pursuant thereto. Grapefruit holds licenses originally issued by the State of California in January 2018 to both manufacture and distribute cannabis products. Grapefruit’s management now owns a controlling interest in IGNG which now owns 100% of Grapefruit’s outstanding shares. As a result, IGNG’s financial reports will consolidate both IGNG’s and Grapefruit’s balance sheet, statement of operation and statement of cash flows and IGNG and Grapefruit will be operated as a single company. IGNG intends to change its name to Grapefruit and to obtain a more appropriate trading symbol as soon as possible. Hereinafter the combined companies will be referred to as “Grapefruit” or the “Company.”

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds licenses to both manufacture and distribute cannabis products which were originally issued in January 2018 and is fully compliant with all applicable laws and regulations to operate its cannabis manufacturing and distribution businesses.

The company is well-focused on sourcing only the “best of the best” raw cannabis materials to create the highest quality, most-trusted and consistent recreational and medical cannabis products for its customers. Grapefruit is committed to ensuring class-leading quality by rigorously testing the purity and potency of its raw materials throughout the manufacturing process and distribution chain.

Grapefruit owns and operates its fully licensed and compliant ethanol extraction laboratory located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. The company’s extraction lab produces high quality, cannabis-derived distillate, also known as “honey oil,” from cannabis flower and “trim.” THC honey oil is one of base cannabis commodities which serves as the active ingredient in everything from infused edibles and tinctures/creams to the cartridges used in vapes and e-cigarettes. Honey oil often sells on the wholesale marketplace for thousands of dollars per liter, with pricing being dependent on quantity purchased, as well as other market factors such as the availability and cost of the underlying flowers and/or trim.

Grapefruit began its extraction operations in May 2019. Plans are in place to expand its honey oil production through the purchase of additional distillation equipment, which is expected to significantly increase the company’s production capacity by the fourth quarter of 2019. Grapefruit’s extraction lab is fully scalable and expansion will be built-out on a two-acre lot owned by Grapefruit at the Coachillin’ site adjacent to its current manufacturing and distribution operation.

Grapefruit selected the City of Desert Hot Springs for its cannabis extraction laboratory, because the city has created a friendly business environment for cannabis-based manufacturers, including incentives like the absence of taxes on cannabis oil production revenues. This affords Grapefruit a fundamental competitive market advantage over other Honey Oil producers.

The California cannabis regulatory scheme is unique in that it requires all cultivators (cannabis farms) and manufacturers (whether producing oils/distillates, infused edibles, tinctures creams or other cannabis products) to sell their products into the legal cannabis wholesale and retail markets exclusively through licensed distributors such as Grapefruit. Grapefruit initially obtained its California recreational and medicinal cannabis distribution license Jan. 4, 2018. In May 2019, Grapefruit was granted its provisional distribution license which is renewable annually, thereby cementing the regulatory foundation necessary to rapidly expand its distribution business.

Grapefruit’s distribution license affords it a twofold strategic advantage: first, to market and sell its own cannabis product lines to retailers throughout California; and second, to buy and resell bulk cannabis flowers and trim as well as all other legal cannabis products to properly licensed distributors and/or retailers throughout California.

The Coachillin’ Canna-Business Park, home to Grapefruit’s current operating facilities and adjacent two-acre parcel of land, is a 160-acre, self-contained legally mapped compound providing the Company with a fully permitted and serviced physical plant from which Grapefruit intends to establish a leading position in the booming California cannabis sector. The parcel was purchased by the Company prior to the Park’s full development, and the value of the land the Company owns has conservatively since doubled in value to over $2 million. Additional long-term benefits of the Coachillin’ compound include agricultural rates for power, which are currently $0.09 per kilowatt hour; the Park’s deep-water well that fully satisfies its need for water; and security expenses shared by all resident businesses. The Coachillin’ Park’s promoters also plan to position the Park, located only 10 miles north of rapidly growing uptown Palm Springs and less than 15 miles from the site of the Coachella and Stagecoach music festivals as a must-see canna-tourism destination.

Grapefruit’s ultimate goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, it plans to roll-out its product lines in other states, such as Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit has plans to build a large, all-inclusive facility that will house a 50,000-square-foot-plus indoor grow canopy, a large extraction laboratory designed to extract both THC and CBD cannabinoids via non-volatile (ethanol) and volatile (butane) processes, a manufacturing space to produce Grapefruit’s vape lines and CBD products, an FDA-certified kitchen for the production of Grapefruit edibles and a distribution facility to sell all products into the entire cannabis market. The indoor grow canopy operation will be outfitted and operated to produce ultra-high-quality flowers and buds, some of which, along with the high-quality trim resulting from cleaning and maintaining the grow, will provide biomass necessary to feed the company’s extraction laboratory. Fueled by this hand cultivated biomass, Grapefruit’s lab will continuously produce pesticide and heavy metal-free world class honey oil to both serve as the active ingredient in all of Grapefruit’s branded and unbranded products and meet the projected ever-growing demand for high quality honey oil in the California market.

Grapefruit’s motto – A High You Can Trust – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacturing, procuring and distributing only the highest quality all-natural cannabis flower, concentrates and related products that are free from pesticides, heavy metals and bacteria. Grapefruit will target its products to all recreational cannabis enthusiasts’ as continuous, consistent cannabis products. By relentlessly adhering to these policies Grapefruit intends to become the Titleist of the Cannabis industry, known for unwavering quality and consistency.

Grapefruit is managed by a team of experts possessing the experience, skill and resources required to succeed in the competitive cannabis marketplace. Founded by brothers Bradley Yourist, CEO, and Daniel Yourist, COO, Grapefruit has expanded to become a group of industry professionals sharing a passion for all things cannabis. Both the CEO & COO are attorneys licensed to practice law the State of California who possess expert cannabis licensing and regulatory expertise and experience, which will allow Grapefruit to deftly navigate the ever changing California regulatory landscape and apply for new cannabis licenses at reduced costs when necessary, rather than having to acquire licenses that are often overvalued and/or pay outside counsel to handle such matters.

Grapefruit also has its own line of cannabis-infused concentrates and edibles. Among the brands now in stores or soon to be launched are:

  • Rainbow Dreams is a new lifestyle brand designed specifically for the recreational cannabis marketplace. The Rainbow Dreams brand captures the anything goes party vibe of the 1970s by offering an array of cannabis products, such as a line of vape carts with unique cannabis strains combined with all-natural flavors for a superior no-burn experience. Rainbow Dreams fills an important niche in the marketplace as a top shelf quality product line that is competitively priced.
  • Sugar Stoned, which Grapefruit acquired in the winter of 2018, has always been a popular cannabis edibles brand which terminated operations when recreational cannabis became legal and required a license in California. Grapefruit purchased the Sugar Stoned brand in 2019 and it is now a Grapefruit portfolio brand consisting of a premium quality cannabis-infused gummy line with eight different flavors: blue raspberry, cherry, grape, peach, pineapple, sour apple, strawberry and watermelon. Grapefruit intends to expand the brand in the near future through the release of a variety of infused cookies.

Grapefruit Boulevard Investments Inc. (IGNG), closed Wednesday's trading session at $0.068, off by 8.1081%, on 127,082 volume with 34 trades. The average volume for the last 3 months is 163,642 and the stock's 52-week low/high is $0.006095/$0.358999997.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade (OTCQB: SGMD) today announced that it has placed a hold on plans to complete a reverse split of its common shares. Per the update, pending a vote by its board of directors, management believes temporarily holding or canceling the reverse split may be the best future course of action. To view the full press release, visit http://cnw.fm/sn0Ez. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how 2020 is shaping up to be a banner year for cannabis markets.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed Wednesday's trading session at $0.009, off by 18.1818%, on 42,775 volume with 358 trades. The average volume for the last 3 months is 7,172,348 and the stock's 52-week low/high is $0.0073/$0.083999998.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Wednesday's trading session at $1.1965, up 25.9474%, on 12,533 volume with 25 trades. The average volume for the last 3 months is 14,424 and the stock's 52-week low/high is $0.600600004/$4.0300002.

Recent News

chart

GP Solutions (OTC: GWPD)

The QualityStocks Daily Newsletter would like to spotlight GP Solutions (GWPD).

GP Solutions (OTC: GWPD) is developing scalable farming systems for soil-less indoor organic farming. The company’s GrowPods are automated micro-farms that use hydroponic technology and unique soil systems to cultivate the highest-quality specialty leaf crops. The system is designed and engineered for ease of use, allowing users to farm year-round in any location of the world, supporting the company’s mission to provide customers with the ability to cultivate their own organic “superfoods.”

GrowPod Design & Function

GrowPod is a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. GrowPods are available as a vertical pod, stacker pod or custom-built pod.

The Stacker Pod is a certified organic soil system that offers growers multiple levels of planting in order to maximize space and produce options with different fruits and vegetables. The Vertical Pod utilizes a vertical hydroponic system. It is affordable, scalable, efficient, automated and sustainable. The output provides customers with fresh and clean produce year-round in any climate. The Custom Pod is built to suit the farmer’s specific crop and grow goals.

Each 320-square-foot GrowPod container will have an annual production capability of up to four times that of outdoor growing methods, dramatically increasing profitability to the grower. The controlled environment of the GrowPod ensures efficient power and water usage in growing a wide range of horticultural and agricultural products in all environments and climates.

Thanks to a combination of hydroponic and certified organic soil systems, crop yields are higher, faster, and more consistent that conventional means. Customers can enjoy an average of eight higher yield crop cycles anywhere in the world.

GrowPod Features:

  • Modular, stackable and mobile
  • Fully insulated, food-grade shipping container
  • Engineered for automation
  • Efficient LED lighting
  • Hydroponic or soil-based platforms
  • Proprietary air and water filtration
  • Climate-controlled
  • Remote monitoring

GP Solutions also offers many services to its customers, including:

  • Shipment and installation service of its shipping container farms
  • On-site training
  • Provision of custom planting and harvesting schedule
  • Provision of growing supplies, seeds, nutrients, packaging, branding and repair materials
  • On-site visits, on-call and scheduled maintenance, and re-supply
  • Remote monitoring and automated control of environmental nutrients, environmental growth factors (PH, temperature, light) and circulation
  • Technical assistance
  • Consulting and custom facility systems design

Competitive Advantage

GrowPods allow cultivation to take place year-round, which maximizes ROI. The systems are sealed from outside pathogens, contaminants, pesticides, and the result is clean and robust crop production.

GP Solutions also has a line of remarkable new proprietary soil mixtures and nutrient lines which contain no animal products. These products are vital, as many other soils and additives can contain harmful pathogens and contaminants that can cause crops to become tainted or fail rigorous testing.

Global Solution

GP Solutions has partnered with the world’s leading food nonprofit companies, including Feeding America, Seeds of Hope, Habitat for Humanity, Meals on Wheels America, L.A. Kitchen, and Farm Bread, to help insecure communities take control of their own food dependence using container farms.

GP Solutions (GWPD), closed Wednesday's trading session at $1.00, up 66.6667%, on 51,450 volume with 7 trades. The average volume for the last 3 months is 361 and the stock's 52-week low/high is $0.600000023/$21.00.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.